Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Devalued and distrusted [[electronic resource] ] : can the pharmaceutical industry restore its broken image? / / John L. LaMattina
| Devalued and distrusted [[electronic resource] ] : can the pharmaceutical industry restore its broken image? / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (137 p.) |
| Disciplina | 338.4/76151 |
| Soggetto topico | Pharmaceutical industry - Corrupt practices |
| ISBN |
1-118-51132-8
1-283-91742-4 1-118-51129-8 |
| Classificazione | MED071000 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts. |
| Record Nr. | UNINA-9910141533103321 |
LaMattina John L
|
||
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Devalued and distrusted [[electronic resource] ] : can the pharmaceutical industry restore its broken image? / / John L. LaMattina
| Devalued and distrusted [[electronic resource] ] : can the pharmaceutical industry restore its broken image? / / John L. LaMattina |
| Autore | LaMattina John L |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (137 p.) |
| Disciplina | 338.4/76151 |
| Soggetto topico | Pharmaceutical industry - Corrupt practices |
| ISBN |
1-118-51132-8
1-283-91742-4 1-118-51129-8 |
| Classificazione | MED071000 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts. |
| Record Nr. | UNINA-9910824681403321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina
| Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (156 p.) |
| Disciplina |
338.4761519
615/.19 |
| Soggetto topico |
Drug development - United States
Pharmaceutical industry - United States Drugs - Research - United States |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-118-15896-2
1-281-93930-7 9786611939304 0-470-43467-8 0-470-43465-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. |
| Record Nr. | UNINA-9910144118603321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina
| Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (156 p.) |
| Disciplina |
338.4761519
615/.19 |
| Soggetto topico |
Drug development - United States
Pharmaceutical industry - United States Drugs - Research - United States |
| ISBN |
1-118-15896-2
1-281-93930-7 9786611939304 0-470-43467-8 0-470-43465-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. |
| Record Nr. | UNINA-9910831068403321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina
| Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (156 p.) |
| Disciplina |
338.4761519
615/.19 |
| Soggetto topico |
Drug development - United States
Pharmaceutical industry - United States Drugs - Research - United States |
| ISBN |
1-118-15896-2
1-281-93930-7 9786611939304 0-470-43467-8 0-470-43465-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. |
| Record Nr. | UNINA-9910841332803321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||